Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its 2018 Annual Report for the period ended 31 December 2018. The filing, dated 12 March 2019, serves as a notification to the SEC and UK Listing Authority regarding the availability of the Annual Report, Annual Summary, and Notice of Annual General Meeting. The document references unaudited preliminary results released on 6 February 2019 but does not contain the full financial statements within this specific text.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the 2018 period. These figures are contained in the referenced 2018 Annual Report and preliminary results announcement. However, the text discloses the following specific financial data points regarding related party transactions and investments as of 31 December 2018:
- Innoviva Inc. Royalties: GSK paid royalties of £209 million to Innoviva Inc. (a 31.7% owned associate) in 2018, compared to £173 million in 2017.
- Innoviva Inc. Payable Balance: £64 million payable to Innoviva as of 31 December 2018 (2017: £53 million).
- Japan Vaccine Co. Ltd (JVC) Sales: GSK sold £43 million of vaccine products to its 50% joint venture, JVC, in 2018 (2017: £41 million).
- JVC Trading Balance: £15 million due to GSK from JVC as of 31 December 2018 (2017: £11 million).
- Investments and Loans: Loans of £5 million to Medicxi Ventures I LP and £6 million to Index Ventures Life VI (Jersey) LP remained due. Equity investments were increased in Kurma Biofund II (£3 million), Apollo Therapeutics LLP (£2 million), and Longwood Founders Fund LP (£0.2 million).
- Qura Therapeutics Liability: Outstanding liability reduced to £4 million as of 31 December 2018.
Material Changes and Operational Context
While specific financial variances are not detailed in this text, the filing highlights several material operational and strategic shifts:
- Risk Management Evolution: GSK evolved its enterprise risk management cycle in 2018 to improve consistency in identifying, managing, and reporting risks.
- Regulatory Environment: The company faces evolving global regulations, including the General Data Protection Regulation (GDPR) in Europe and ongoing tax reform initiatives driven by the OECD and European Commission.
- Commercial Practices: In October 2018, GSK announced changes allowing fair market value payments to expert practitioners in a limited number of countries, accompanied by new controls and expanded reporting of payments to healthcare professionals.
- Supply Chain and Brexit: The company is actively addressing the impact of Brexit on supply chain management and quality oversight between the UK and the EU, developing contingency plans to avoid supply interruptions.
Guidance, Outlook, Risks, and Contingencies
Forward-Looking Statements: GSK cautions that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
Principal Risks and Uncertainties: The filing details extensive risk categories, including:
- Patient Safety: Risks related to adverse events, product liability litigation (including class actions), and regulatory actions. The company notes it is a defendant in significant product liability lawsuits.
- Product Quality: Risks of non-compliance with Good Manufacturing Practices (cGMP), supply chain failures, and product recalls.
- Financial Controls: Risks regarding tax law changes (e.g., US Tax Cuts and Jobs Act), treasury activities, and financial reporting compliance.
- Anti-Bribery and Corruption (ABAC): Ongoing government investigations regarding China and other business operations. A self-monitorship arrangement with US authorities concluded in September 2018.
- Commercial Practices: Risks of downward price pressure, declining emerging market growth, and negative foreign exchange impacts.
- Privacy and Data Security: Risks of non-compliance with diverse global data privacy laws and cybersecurity threats from nation-states and organized criminals.
- Research Practices: Risks related to patent expiration, generic competition, and data integrity in clinical trials.
- Third Party Oversight: Risks associated with suppliers, distributors, and partners failing to meet contractual or regulatory obligations.
- Environment, Health & Safety: Potential liabilities for environmental remediation, particularly under US laws.
- Supply Continuity: Risks of disruption from natural events, pandemics, or geopolitical instability.
Investor Verification Checklist
- Verify the full 2018 Annual Report and preliminary results announcement (released 6 February 2019) for complete revenue, profit, and cash flow figures not included in this summary.
- Review Note 45 ('Legal proceedings') in the Annual Report for details on unresolved product liability lawsuits and ongoing government investigations.
- Assess the impact of the October 2018 changes to commercial practices regarding payments to healthcare professionals.
- Monitor the status of ongoing ABAC investigations in China and other jurisdictions.
- Evaluate the company's specific contingency plans for Brexit-related supply chain disruptions.
- Check the status of patent expirations and the potential impact of generic competition on key revenue drivers.